Corbus Pharmaceuticals has announced the release of an abstract for its first-in-human clinical study of CRB-701, indicating progress in its drug development pipeline. The upcoming poster ...

The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...

Corbus’ pipeline includes CRB-701 ... use does not imply affiliation or endorsement by these companies. Corbus Pharmaceuticals Holdings NewsMORE Related Stocks ...

Corbus’ pipeline includes CRB-701 ... not imply affiliation or endorsement by these companies. Source: Corbus Pharmaceuticals Holdings, Inc. The views and opinions expressed herein are the ...

To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $9.26, as investors respond to a series of market headwinds. According to InvestingPro data, the stock's ...

Corbus Pharmaceuticals Holdings ... Besides CRB-701, their pipeline includes other promising therapeutics such as CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ ... treatments in oncology and obesity by leveraging scientific innovation. Besides CRB-701, their pipeline includes other promising therapeutics such as ...